Tissue Proteomics for Biomarker Discovery and Target Validation

Traditional tissue analysis methods, such as those based on affinity-based probes, often suffer from limited specificity and poor quantitative accuracy. While RNA sequencing provides valuable gene expression data, it often correlates poorly with actual protein abundance due to factors such as translational regulation, protein degradation, and post-translational modifications.

Biognosys’ mass spectrometry-based TrueDiscovery tissue proteomics platform provides deep, unbiased, and label-free protein profiling with peptide-level resolution, capturing the full complexity of the proteome. From just 1 mg of fresh-frozen tissue or a single FFPE slide, up to 12,000 protein groups are quantified, covering intracellular, secreted, and surface proteins. This flexible and high-throughput approach supports a range of applications from biomarker discovery and mechanism of action studies to the identification of therapeutic targets for precision therapies.

Download Flyer